top of page
About
Team
Management
Board Of Directors
Scientific Advisory Board
Scientific and Regulatory Advisors
Clinical
News
Contact
Targeted Solutions for Weight Management and Metabolic Health
August 13,2025
Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study of RDX-002 in Post-GLP-1 Management
Read more...
February 06, 2025
Response Pharmaceuticals Announces Early Completion of Enrollment of a Phase 2 Study Evaluating RDX-002 Treating Patients Discontinuing GLP-1 Agonists
Read more...
October 17, 2024
Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week
Read more...
April 23, 2024
Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial
Read more
August 17, 2023
Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002
Read more
November 21, 2022
Response Pharmaceuticals Closes Series A Financing
Read more
About
Team
Management
Board Of Directors
Scientific Advisory Board
Scientific and Regulatory Advisors
Clinical
News
Contact
bottom of page
